CLOTTAFACT 1,5 G/100 ML, POUDRE ET SOLVANT POUR SOLUTION INJECTABLE clinical trials

FORMAT Study : Use of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusion - evaluation by rotem viscoelastometry (pilot single-center study).

This study looks at how a medicine called fibrinogen, along with blood transfusions, can help patients with blood cancer who are bleeding. It aims to improve their blood's ability to clot, especially when normal platelet transfusions haven't worked.